Ferrer Adjustable Speaking Valve for Early Phonation in a Deconditioned Patient.
| Autor: | Cartaya R; Family Medicine, Nova Medical Services, Miami, USA., Rizvi SAA; Biomedical Sciences, Larkin University, Miami, USA., Manara V; Pulmonary and Critical Care, Ferrer Pulmonary Institute, Hallandale Beach, USA., Tesch ML; Research and Development, Dr. Ferrer Biopharma, Hallandale, USA., Franck R; Pulmonary and Critical Care Medicine, Cleveland Clinic Florida, Weston, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Jun 10; Vol. 16 (6), pp. e62081. Date of Electronic Publication: 2024 Jun 10 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.62081 |
| Abstrakt: | A patient with multiple comorbidities and an eight-year history of tracheostomy was being treated for tracheitis. At this point, she became incapable of using regular speaking valves, and multiple attempts to reintroduce the speaking valve failed. A Ferrer adjustable speaking valve (FASV) was designed with gradations of outflow closure, allowing air to go through the vocal cords for phonation. The FASV was offered to her through the compassionate use program at the FDA. At 20% initial closure, the patient was able to tolerate the valve and was advanced to 50% closure, at which point she could phonate partially. The use of the valve was terminated at the time of her transfer, 23 days after the initiation of use. This suggests the safety and possible efficacy of using an adjustable speaking valve earlier than regular valves, allowing patients to communicate earlier and further exercise their diaphragms. Competing Interests: Dr. Ferrer Biopharma holds the patent of the Ferrer Adjustable Speaking Valve (FASV) (Copyright © 2024, Cartaya et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|